RUNX1 and acute myeloid leukemia: Elucidation of the deregulated intracellular signaling pathways downstream of CSF3R and RUNX1 mutations will help to identify druggable targets, with the goal of eliminating leukemia-predisposed HSPCs and/or specifically targeting CN/AML blasts.